My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

10.29 -0.64 (-5.86%)
Streaming Delayed Price Updated: 1:25 PM EDT, Sep 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 187,940
Open 10.40
Bid (Size) 10.29 (5)
Ask (Size) 10.30 (3)
Prev. Close 10.93
Today's Range 10.22 - 10.40
52wk Range 8.930 - 30.36
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
CMS Grants Transitional Pass-Through Status for Gozellix
From Telix Pharmaceuticals Limited
Via GlobeNewswire

Performance

YTD
-31.4%
-31.4%
1 Month
-15.7%
-15.7%
3 Month
-37.3%
-37.3%
6 Month
-44.0%
-44.0%
1 Year
-32.1%
-32.1%

More News

Read More
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
From Telix Pharmaceuticals Limited
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Agilon, Albany International, Fluor, and Telix and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
Telix Gets Second FDA Rejection For Kidney Cancer Drug
Via Benzinga
Cooper Companies Posts Downbeat Sales, Joins NetApp, Urban Outfitters, Nvidia And Other Big Stocks Moving Lower In Thursday Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference
From Telix Pharmaceuticals Limited
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation – TLX
From Rosen Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – TLX
From DJS Law Group
Via Business Wire
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
From Telix Pharmaceuticals Limited
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Telix Pharmaceuticals Limited - American Depositary Shares publicly traded?
Yes, Telix Pharmaceuticals Limited - American Depositary Shares is publicly traded.
What exchange does Telix Pharmaceuticals Limited - American Depositary Shares trade on?
Telix Pharmaceuticals Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares?
The ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares is TLX on the Nasdaq Stock Market
What is the current price of Telix Pharmaceuticals Limited - American Depositary Shares?
The current price of Telix Pharmaceuticals Limited - American Depositary Shares is 10.29
When was Telix Pharmaceuticals Limited - American Depositary Shares last traded?
The last trade of Telix Pharmaceuticals Limited - American Depositary Shares was at 09/24/25 01:25 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.